Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Liso-cel for aggressive B-cell NHL

Raúl Córdoba • 22 Jun 2020
EHA 2020
Lymphoma Non-Hodgkin Lymphoma CAR-T Lisocabtagene maraleucel
TRANSCEND-PILOT-017006

Raul Cordoba, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, discusses results from the Phase II TRANSCEND-PILOT-017006 study (NCT03483103) evaluating lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in relapsed/refractory large B-cell non-Hodgkin lymphoma (NHL) patients. Specifically discussed is the potential impact of this CAR T-cell therapy on elderly, unfit patients with comorbidities. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Raúl Córdoba

2:03
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL
Raúl Córdoba • 7 Oct 2023
2:08
The differences in outcomes and treatment in CLL patients with mutated and unmutated IGHV
Raúl Córdoba • 7 Oct 2023
2:12
Real-world safety and efficacy of first- and second-generation BTK inhibitors in CLL
Raúl Córdoba • 7 Oct 2023
2:20
Clinical relevance of geriatric assessment
Raúl Córdoba • 22 Jun 2020

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals